<p>Humanigen, Inc. (OTCQB: <a href= "https://www.otcmarkets.com/stock/HGEN">HGEN</a>) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman & CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of "GM-CSF" pathway science for COVID-19 patients.</p>

Humanigen, Inc. (OTCQB: HGEN) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman & CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of "GM-CSF" pathway science for COVID-19 patients.

<p>Humanigen, Inc. (OTCQB: <a href="https://www.otcmarkets.com/stock/HGEN" rel="noopener noreferrer">HGEN</a>) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman &amp; CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of "GM-CSF" pathway science for COVID-19 patients.</p>

Humanigen, Inc.

OTC Markets presents our podcast series on the OTCQB Market, where we interview the entrepreneurs behind the companies that trade on the venture market.

Share Humanigen, Inc.

Sign up to save your podcasts

Humanigen, Inc.

Humanigen, Inc.